Phase III COUGH-1 and COUGH-2 trials evaluating gefapixant for refractory or unexplained chronic cough meet primary endpoints

Both studies showed a statistically significant reduction in 24-hour coughs per hour at Week 12, and 24-hour coughs per hour at week 24. Gefapixant is a purinergic P2X3 receptor antagonist; P2X3 receptors are expressed in afferent neurones that transmit pain perception.


Biospace Inc.